Zhijun Shen1,2, Chen Chen3, Jianhai Sun4, Jingsong Huang5, Shiguo Liu6. 1. Department of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. 2. Department of Clinical Laboratory, Hubei No. 3 People's Hospital of Jianghan University, No. 26 Zhongshan Avenue, Wuhan, 430033, Hubei, China. 3. Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China. 4. Department of Oncology, Hubei No. 3 People's Hospital of Jianghan University, Wuhan, 430033, Hubei, China. 5. Department of Transfusion, School of Medicine, Xiang'an Hospital of Xiamen University, Xiamen University, Xiamen, 361101, Fujian, China. JingsongHuangasd@163.com. 6. Department of Clinical Laboratory, Hubei No. 3 People's Hospital of Jianghan University, No. 26 Zhongshan Avenue, Wuhan, 430033, Hubei, China. llsgg518@163.com.
Abstract
BACKGROUND: Targeted cancer therapy has shed light on the treatment of tumor, especially for patients with non-small cell lung cancer. However, only a limited portion of NSCLC patients carrying specific mutations showed an ideal drug response. In addition, DNA methylation status showed a great potential for cancer detection and prognosis prediction. METHODS: Bisulfite sequencing was performed to analyze the DNA methylation of WIF1 promoter in cfDNA and tumor tissue samples collected from NSCLC patients. PFS and OS analyses were carried out to evaluate the prognosis of gefitinib treatment in patients with differential levels of WIF1 DNA methylation. Quantitative real-time PCR was used to analyze the expression of WIF1 mRNA, while immunohistochemistry was performed to assess the expression of WIF1 protein. Furthermore, ELISA was carried out to evaluate the WIF1 activity in plasma. RESULTS: The DNA methylation level of WIF1 promoter was lower in the cfDNA of NSCLC patients with a complete or partial response to gefitinib, and NSCLC patients with hypomethylated WIF1 showed better PFS and OS. The DNA methylation of WIF1 promoter in the resected tumor tissues was consistent with WIF1 DNA methylation in cfDNA, indicating that cfDNA was mainly derived from lung cancer tissues. As a result, the expression of WIF1 in tissue samples and the WIF1 activity in plasma was inhibited in patients with hypermethylated WIF1. Moreover, the cell viability of gefitinib-resistant cells was decreased by the suppressed WIF1 methylation in vitro. And the expression level of WIF1 mRNA was higher in gefitinib-resistant cells overexpressing ALKBH5, a known suppressor of WIF1 methylation. CONCLUSION: In summary, the findings of this study demonstrated that the level of WIF1 methylation in cfDNA was associated with the insusceptibility of gefitinib in the treatment of lung cancer.
BACKGROUND: Targeted cancer therapy has shed light on the treatment of tumor, especially for patients with non-small cell lung cancer. However, only a limited portion of NSCLCpatients carrying specific mutations showed an ideal drug response. In addition, DNA methylation status showed a great potential for cancer detection and prognosis prediction. METHODS: Bisulfite sequencing was performed to analyze the DNA methylation of WIF1 promoter in cfDNA and tumor tissue samples collected from NSCLCpatients. PFS and OS analyses were carried out to evaluate the prognosis of gefitinib treatment in patients with differential levels of WIF1 DNA methylation. Quantitative real-time PCR was used to analyze the expression of WIF1 mRNA, while immunohistochemistry was performed to assess the expression of WIF1 protein. Furthermore, ELISA was carried out to evaluate the WIF1 activity in plasma. RESULTS: The DNA methylation level of WIF1 promoter was lower in the cfDNA of NSCLCpatients with a complete or partial response to gefitinib, and NSCLCpatients with hypomethylated WIF1 showed better PFS and OS. The DNA methylation of WIF1 promoter in the resected tumor tissues was consistent with WIF1 DNA methylation in cfDNA, indicating that cfDNA was mainly derived from lung cancer tissues. As a result, the expression of WIF1 in tissue samples and the WIF1 activity in plasma was inhibited in patients with hypermethylated WIF1. Moreover, the cell viability of gefitinib-resistant cells was decreased by the suppressed WIF1 methylation in vitro. And the expression level of WIF1 mRNA was higher in gefitinib-resistant cells overexpressing ALKBH5, a known suppressor of WIF1 methylation. CONCLUSION: In summary, the findings of this study demonstrated that the level of WIF1 methylation in cfDNA was associated with the insusceptibility of gefitinib in the treatment of lung cancer.
Authors: Sébastien Couraud; Felipe Vaca-Paniagua; Stéphanie Villar; Javier Oliver; Tibor Schuster; Hélène Blanché; Nicolas Girard; Jean Trédaniel; Laurent Guilleminault; Radj Gervais; Nathalie Prim; Michel Vincent; Jacques Margery; Sébastien Larivé; Pascal Foucher; Bernard Duvert; Maxime Vallee; Florence Le Calvez-Kelm; James McKay; Pascale Missy; Franck Morin; Gérard Zalcman; Magali Olivier; Pierre-Jean Souquet Journal: Clin Cancer Res Date: 2014-07-10 Impact factor: 12.531
Authors: Oliver Gautschi; Colette Bigosch; Barbara Huegli; Monika Jermann; Arthur Marx; Eveline Chassé; Daniel Ratschiller; Walter Weder; Markus Joerger; Daniel C Betticher; Rolf A Stahel; Annemarie Ziegler Journal: J Clin Oncol Date: 2004-10-15 Impact factor: 44.544
Authors: Jie Cheng; Tim Holland-Letz; Markus Wallwiener; Harald Surowy; Katarina Cuk; Sarah Schott; Andreas Trumpp; Klaus Pantel; Christof Sohn; Andreas Schneeweiss; Barbara Burwinkel Journal: Breast Cancer Res Treat Date: 2018-01-16 Impact factor: 4.872
Authors: Sun Wook Cho; Jae-Yeon Yang; Hyun Jin Sun; Ju Yeon Jung; Sun Ju Her; Hwa Young Cho; Hyung Jin Choi; Sang Wan Kim; Seong Yeon Kim; Chan Soo Shin Journal: Bone Date: 2009-02-27 Impact factor: 4.398